SMB·BIO

Celltrion's Herzuma wins Brazil federal tender for 7th consecutive year

by
Choi Eun-ji
Published : Nov. 17, 2026 - 09:07:46
    • Copy Completed!

View Korean Original

Celltrion to supply about 1 million vials exclusively through end of next year, securing 80% of public-market volume; company holds 50% market share in Brazil and plans to expand private-sector presence; Omrikloe, Eydenzel and Aptozma to strengthen Latin America portfolio

Herzuma, a biosimilar for breast and gastric cancer treatment. [Celltrion]
Herzuma, a biosimilar for breast and gastric cancer treatment. [Celltrion]

Celltrion's breast and gastric cancer treatment Herzuma (trastuzumab) has won a Brazilian federal government tender for the seventh consecutive year in Latin America's largest pharmaceutical market.

Celltrion announced Tuesday that Herzuma has secured the Brazilian federal tender every year since its first award in 2020, the year after the product launched.

Under the latest contract, Celltrion's Brazilian subsidiary will exclusively supply about 1 million vials of Herzuma through the end of 2027. The tender covers roughly 80% of Brazil's public-market volume for trastuzumab, giving the company a stable sales base.

Brazil's pharmaceutical market is divided between a public segment overseen by the federal government and a private segment where hospitals select products independently, in roughly an 80-to-20 ratio. Celltrion's Brazilian unit has dominated the public channel — the more critical of the two — through a localized direct-sales strategy and strong supply capabilities. Its ability to deliver 1 million vials to a single country without disruption was also a key factor in winning the tender.

Herzuma currently holds about 50% of Brazil's trastuzumab market, according to IQVIA, outpacing both the originator and rival biosimilars to rank first in prescriptions. Because many leading Brazilian physicians practice at both public and private institutions, Celltrion plans to leverage its established credibility in the public sector to grow its share in the private market as well.

Celltrion intends to accelerate growth in Brazil and across Latin America by introducing additional products. Omrikloe (omalizumab), a treatment for chronic spontaneous urticaria that launched as a first-mover product late last year, has already won a tender from the state government of Santa Catarina and captured about 26% of the private market, gaining traction quickly.

Alongside this, Eydenzel (aflibercept), a treatment for ophthalmic diseases, and Aptozma (tocilizumab), a treatment for autoimmune diseases, are both on track for launch by year-end, with preparatory work already underway. The company plans to accelerate early market entry by expanding its specialist sales force and strengthening its medical network.

The consecutive tender wins have demonstrated Celltrion's capacity to supply 1 million vials on schedule to a single country, while also establishing a foothold it can use to drive the early rollout of high-margin follow-on products across Latin America.

"The sustained results in Brazil reflect the combination of a sales strategy tailored to the local market, a solid network, and strong product credibility," said Kang Gyeong-du, Celltrion's head of Latin America. "We will build on our existing direct-sales strengths by adding follow-on products to expand our presence in Brazil and broaden our growth opportunities across Latin America."


silverpaper@heraldcorp.com
This content was produced with the assistance of AI translation services.

MOST READ